Media coverage about Magellan Health (NASDAQ:MGLN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Magellan Health earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.2853318200261 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Coventry Health Care (CVH) vs. Magellan Health (MGLN) Head-To-Head Contrast (americanbankingnews.com)
- Magellan Health Inc (MGLN) Expected to Announce Quarterly Sales of $1.62 Billion (americanbankingnews.com)
- Jonathan N. Rubin Sells 17,443 Shares of Magellan Health Inc (MGLN) Stock (americanbankingnews.com)
- Magellan Health Inc (MGLN) CEO Barry M. Smith Sells 13,367 Shares (americanbankingnews.com)
- Magellan Health Inc (MGLN) Expected to Post Earnings of $2.30 Per Share (americanbankingnews.com)
MGLN has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Magellan Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. BidaskClub downgraded shares of Magellan Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 19th. KeyCorp set a $105.00 price objective on shares of Magellan Health and gave the company a “buy” rating in a research report on Friday, December 1st. Jefferies Group reaffirmed a “buy” rating and set a $94.00 price objective on shares of Magellan Health in a research report on Friday, October 13th. Finally, Raymond James Financial reaffirmed a “hold” rating on shares of Magellan Health in a research report on Saturday, December 2nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Magellan Health has a consensus rating of “Buy” and a consensus price target of $96.00.
Magellan Health (NASDAQ:MGLN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.24. Magellan Health had a net margin of 1.68% and a return on equity of 9.20%. The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm earned $1.39 EPS. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. research analysts expect that Magellan Health will post 5.19 earnings per share for the current year.
In other Magellan Health news, CEO Mostafa Kamal sold 1,154 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $92.00, for a total value of $106,168.00. Following the completion of the transaction, the chief executive officer now owns 1,154 shares in the company, valued at approximately $106,168. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Clapper Caskie Lewis sold 59,313 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $93.99, for a total transaction of $5,574,828.87. Following the completion of the transaction, the insider now owns 48,474 shares of the company’s stock, valued at approximately $4,556,071.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,101 shares of company stock valued at $10,412,588. Insiders own 5.00% of the company’s stock.
About Magellan Health
Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.